Trofinetide Completed Phase 2 Trials for Fragile X Syndrome (FXS) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01894958A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome